PARP Inhibitors Very Likely Work in Ovarian Cancer without BRCA1 or BRCA2 Mutations

PARP Inhibitors Very Likely Work in Ovarian Cancer without BRCA1 or BRCA2 Mutations

SGO2017

2 years
839 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses how the use of PARP Inhibitors work for Ovarian Cancer treatment without BRCA mutations. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Up Next Autoplay